Physician profile
David Rosenberg
NPI 1629033253
$21,034.29
in general payments reported to CMS, 2019-2025
44 companies · $3,326 in 2025
The $3,326 reported for 2025 was more than what 94% of Pediatric Pulmonology providers received nationally (typical 2025 total: $140).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $2,720 · 2020: $2,661 · 2021: $3,531 · 2022: $3,050 · 2023: $3,271 · 2024: $2,475 · 2025: $3,326.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $8,893 · Education: $180.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $8,892.92 |
| Education | $179.75 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astrazeneca Pharmaceuticals Lp | $3,543.49 | 2019-2025 | Tezspire, Fasenra, Symbicort |
| Genzyme Corporation | $1,905.66 | 2019-2025 | |
| Glaxosmithkline, LLC. | $1,832.46 | 2019-2025 | Nucala |
| Sobi, INC | $1,663.20 | 2019-2024 | |
| Regeneron Healthcare Solutions, INC. | $1,488.79 | 2020-2025 | Dupixent |
| Genentech USA, INC. | $1,351.09 | 2019-2025 | Xolair |
| Amgen INC. | $1,085.81 | 2021-2025 | Tezspire |
| Novartis Pharmaceuticals Corporation | $955.89 | 2020-2025 | |
| Baxter Healthcare | $910.12 | 2022-2025 | Hillrom - Vest System Model 105 Home Care |
| Covis Pharma Gmbh | $908.13 | 2019-2023 | |
| Chiesi USA, INC. | $808.23 | 2019-2021 | |
| Advanced Respiratory, INC | $548.11 | 2019-2021 | |
| Harmony Biosciences LLC | $513.89 | 2024-2025 | |
| Pfizer INC. | $391.23 | 2019-2024 | |
| Takeda Pharmaceuticals U.S.A., INC. | $376.61 | 2020-2025 | Cuvitru, Hyqvia |
Show all 43 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Jazz Pharmaceuticals INC. | $356.19 | 2019-2022 | |
| Teva Pharmaceuticals USA, INC. | $294.54 | 2019-2023 | |
| Philips North America LLC | $293.25 | 2019-2021 | |
| Gilead Sciences, INC. | $232.99 | 2019-2024 | Veklury |
| Kaleo, INC. | $209.10 | 2020-2024 | Auvi-Q |
| Csl Behring | $162.97 | 2022-2025 | Hizentra |
| Insmed, INC. | $145.72 | 2020-2025 | Brinsupri, Arikayce |
| Shire North American Group INC | $143.17 | 2019 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $126.34 | 2019-2023 | Spiriva Respimat |
| Phadia US INC. | $107.53 | 2019-2022 | |
| Pharming Healthcare, INC. | $84.41 | 2023-2025 | Ruconest |
| Sanofi-Aventis U.S. LLC | $78.86 | 2019-2024 | |
| Allergan, INC. | $76.16 | 2019-2020 | |
| Electromed, INC. | $49.22 | 2019-2021 | |
| Masimo Corporation | $45.70 | 2020 | |
| Biogen, INC. | $41.16 | 2019-2020 | |
| Tactile Systems Technology INC | $39.97 | 2023-2024 | Entre Plus, Flexitouch Plus |
| Alk-Abello, INC | $35.75 | 2019-2023 | Standardized Mite D. Farinae, Timothy, Standardized, Pre-Pen |
| Nestle Healthcare Nutrition INC. | $32.48 | 2021 | |
| Aimmune Therapeutics, INC. | $28.52 | 2025 | Zenpep |
| Hikma Pharmaceuticals USA | $26.75 | 2022 | |
| Vapotherm INC | $26.54 | 2022 | |
| Actelion Pharmaceuticals US, INC. | $25.07 | 2023 | Uptravi, Opsumit |
| Gc Biopharma USA, INC. | $22.12 | 2025 | Alyglo |
| Resmed Corp | $20.08 | 2024 | |
| Mission Pharmacal Company | $19.18 | 2019 | |
| Circassia INC. | $16.05 | 2020 | |
| Adma Biomanufacturing LLC | $11.76 | 2021 |
1 company reported research payments only; those appear in the research section below.
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw David Rosenberg listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.